Top Markets
Coin of the day
Imunon, Inc. Imunon, Inc.

Imunon, Inc.

CLSN
Rank in Stocks #35102
Imunon, Inc. is a biotechnology firm in the clinical development stage,... Imunon, Inc. is a biotechnology firm in the clinical development stage, dedicated to innovating and commercializing DNA-centric immunotherapies, vaccines, and targeted chemotherapy solutions. Its primary pipeline assets include GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a unique formulation of doxorubicin encapsulated in heat-activated liposomes, currently being assessed for a variety of cancer indications. Furthermore, the company is advancing two early-phase platform technologies aimed at developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA treatments. Established in 1982, Imunon, Inc. maintains its operational base in Lawrenceville, New Jersey.
Share Price
$1.96
Last synced: 2022-09-20
Market Cap
$4.46M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Imunon, Inc. (CLSN)

Category

P/S ratio for Imunon, Inc. (CLSN)
P/S ratio as of 2026 TTM: 0
According to Imunon, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Imunon, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE